Bibliography
- GOODMAN SG, FITCHETT D, ARMSTRONG PW, TAN M, LANGER A; INTEGRILIN AND ENOXAPARIN RANDOMIZED ASSESSMENT OF ACUTE CORONARY SYNDROME TREATMENT (INTERACT) TRIAL INVESTIGATORS: Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation (2003) 107(2):238–244.
- ••The INTERACT study; a landmark studyevaluating combination therapy using eptifibatide and enoxaparin in the medical stabilisation of patients with ACS.
- SALAM AM, SUWAIDI JA: Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease. Expert Opin. Investig. Drugs (2002) 11(11):1645–1658.
- •An excellent review of clinical trials of platelet GP IIb/IIIa inhibitors.
- HIRSH J, WARKENTIN TE, RASCHKE R, GRANGER C, OHMAN EM, DALEN JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1998) 114(5, Suppl.):489S–510S.
- COHEN M, THEROUX P, WEBER S et al.: Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int. .1. Cardiol (1999) 71:273–281.
- COHEN M, THEROUX P, BORZAK Set al.: Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. Am. Heart J. (2002) 144(3):470–477.
- FERGUSON JJ, ANTMAN EM, BATES ER et al.: The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 study. I Am. Coll. Carcliol (2001) 37:365A.
- BOERSMA E, HARRINGTON RA, MOLITERNO DJ et al: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 359(9302):189–198.
- JAMES S, ARMSTRONG P, CALIFF R et al.: Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. Eur. Heart .1. (2002) 23:1538-1545.
- MUKHERJEE D, MAHAFFEY KW, MOLITERNO DJ et al: Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). Am. Heart J. (2002) 144:995–1002.
- BLAZING MA, DE LEMOS JA, DYKE CK, CALIFF RM, BILHEIMER D, BRAUNWALD E: The A-to-Z Trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am. Heart J. (2001) 142(2): 211–217.
- •The goal of the 'A Phase' of the A to Z trial is to compare the efficacy and safety of UF heparin versus enoxaparin as adjunctive therapy to baseline treatment with tirofiban and aspirin in patients with ACS.
- CANNON CP, WEINTRAUB WS, DEMOPOULOS LA et al: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. For the TACTICS-Thrombolysis in Myocardial Infarction 18 Investigators. N Engl. J. Med (2001) 344(25):1879–1887.
- •This study evaluated conservative and invasive treatment strategies in ACS in the current era. In patients who were treated with tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events. These data support a policy involving broader use of the early inhibition of GP IIb/IIIa in combination with an early invasive strategy in such patients.
- SYNERGY EXECUTIVE COMMITTEE: Superior Yield of the New strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa inhibitors. The SYNERGY trial: study design and rationale. Am. Heart J. (2002) 143(6):952–960.
- •The ongoing SYNERGY trial will address the efficacy of enoxaparin versus UF heparin in a population of patients who are all treated with an early invasive therapy.